10x Genomics (TXG) Q3 2026 earnings review
10x Genomics raises its Atera shipment plan, while core sales stall
10x Genomics, the maker of gene-mapping lab tools, kept sales steady while starting deliveries of its flagship Atera machine. Total revenue edged up 1% from a year ago to $151 million as chemical kit sales for spatial tissue mapping rose 16%, making up for a 43% drop in equipment sales. Chief executive Serge Saxonov raised the full-year outlook, which by our math points to 7% growth in the fourth quarter.
| Sales excluding patent settlements | $150.2M +1.5% from a year ago |
|---|---|
| Spatial chemical kit sales | $41.2M +16.4% from a year ago |
| 2026 Atera machine shipment plan | Raised to ~50 up from ~40 units previously |
| Full-year revenue outlook | Raised $10M middle of the range: 5% underlying growth |
⚖️ Verdict: 🟢 Bullish
The story got better because the Atera factory ramp is ahead of schedule and older spatial systems did not suffer a pre-launch slump. Management lifted this year's Atera delivery target from 40 machines to 50 and set a pace of 50 per quarter for next year. One caution: lower prices on single-cell kits held that core division to 1% growth, and heavy fourth-quarter machine deliveries will cut gross margin by over 10 percentage points.
The question now is whether Atera brings in new budgets or mostly replaces spending by existing Xenium customers. If it expands the market, total spatial sales will accelerate sharply in 2027; if it cannibalizes, older kit sales will slow as the new machines arrive. Fourth-quarter spatial revenue and next year's initial outlook in February will tell.
🐂 Bull Case
Atera Production Ramp Beats Early Targets
"The biggest highlight of the quarter was the start of commercial shipments of Atera," chief executive Serge Saxonov said. Atera is the life-science toolmaker's new machine for mapping gene activity across tissue samples. Finance chief Adam Taich said the company delivered a couple of machines in late September and raised its full-year shipment plan from 40 units to 50.
Manufacturing capacity and customer training, rather than buyer interest, limit how fast 10x Genomics can deliver these systems. Saxonov told analysts that "thinking about 50 a quarter between those constraints is about the right number" as the business enters 2027. That pace gives the California group a clear path to roughly 200 placements next year.
What to watch: fourth-quarter instrument revenue, which arrives with the full-year report in February. Delivering the remaining 48 machines on schedule will prove the factory can hit that 50-unit quarterly pace.
Spatial Chemical Kits Defy the Pre-Launch Pause
10x Genomics sells both laboratory machines and the chemical kits, known as consumables, required to run each experiment. Spatial biology products map where cells sit inside tissue using the older Visium and Xenium systems alongside the new Atera platform. Taich had warned that chemical sales for spatial systems would dip from the second quarter as laboratories waited for Atera.
Instead, spatial consumables grew 16.4% from a year ago to $41.2 million, holding steady near the second quarter's $42.3 million level. Existing Xenium owners kept running experiments at a fast clip even while holding back on machine purchases. Spatial kits now bring in 30.7% of all consumable sales, up from 27.7% a year earlier.
What to watch: spatial consumable growth in the fourth quarter, when the first Atera chemical kits ship. Another double-digit gain will show that Atera adds to Xenium usage rather than replacing it.
Positives this quarter didn't test
Three strategic initiatives advanced in the third quarter without contributing measurable revenue to the results.
- Sentira cloud software: uses NVIDIA computing and Anthropic's Claude AI to analyze cell data; a future disclosure of software sales would test its commercial value.
- Clinical diagnostics push: added a cancer study with the Fred Hutch research center ahead of opening an internal diagnostic lab next year; clinical revenue after launch will test adoption.
- Multiomics protein tools: paired newly acquired Proteintech Genomics panels with single-cell workflows; faster single-cell consumable growth in 2027 would show customers are paying more per cell.
🐻 Bear Case
Lower Prices Hold Back Single-Cell Revenue
Single-cell analysis, which studies individual cells using Chromium machines, remains the company's biggest business at 61.8% of total sales. Consumable revenue in this division rose 0.7% from a year ago to $93.1 million, slowing from 3.1% growth in the second quarter. Taich said the flat result was "supported by double-digit growth in reaction volumes given strong demand for Flex Apex."
Flex Apex is a newer chemical kit that lets scientists run larger batches at a lower price per test. Saxonov noted that Flex Apex is heading toward a majority of single-cell test volumes. Because the price drop matches the jump in test volumes, the division gets almost no revenue lift from scientists running more experiments.
What to watch: single-cell consumable revenue in the first quarter of 2027, once most customers have finished switching to Flex Apex. A failure to accelerate above 5% growth would show that lower prices permanently shrank the division's revenue potential.
Equipment Sales Plunge and New Machines Will Cut Margins
Gross margin jumped 7.6 percentage points from a year ago to 75.0%, as the cost of making products fell from 32.7% of revenue to 25.0%. That boost happened because customers stopped buying lower-margin hardware while waiting for Atera, and because inventory write-downs fell.
- Total instrument revenue: $6.9 million, down 42.8% from a year ago
- Spatial instrument revenue: $3.1 million, down 56.5%
- Single-cell instrument revenue: $3.8 million, down 23.2%
- Research and development costs: 35.1% of revenue, down 3.3 percentage points on lower staffing and lab gear spend
Shipping ~48 Atera machines in the fourth quarter will reverse that mix benefit. Taich said the team will "anticipate gross margins will be in the low to mid-60s for Q4" and warned that 2027 margins will also fall during an equipment-heavy year.
What to watch: fourth-quarter gross margin against the low-to-mid 60s target. A drop below 60% would signal higher-than-planned factory and installation costs for the new platform.
Big Claims on AI and Orders Rest on Secret Numbers
"Nearly all of the world's top 20 biopharma companies have now purchased Atera systems or services through Catalyst," Saxonov told investors. Catalyst Research Services is an internal laboratory where 10x Genomics runs tissue samples for clients who have not bought a machine. Over 100 clients booked projects there in its first five months.
When asked how many drugmakers bought a machine versus sending samples to the service lab, Saxonov refused to split the figure. He also told analysts that "we don't really share our backlog numbers or our order numbers" for Atera, and provided no dollar figure for AI-related demand. Total deferred revenue on the balance sheet slipped to $31.5 million from $34.4 million in December, showing no visible deposit surge.
What to watch: the annual report's backlog and machine installed-base disclosures in February. Without hard order numbers, investors cannot tell how much demand lasts beyond the first few quarters of shipments.
💲 Other KPIs
Cash and marketable securities rose by $23.6 million from the second quarter and 19.4% from a year ago. The life-science company carries no bank debt and continues to add cash despite reporting a $19.4 million quarterly accounting net loss, because non-cash stock compensation and depreciation exceed its operating losses.
Inventory climbed 22.8% from the second quarter's $52.6 million and sits 14.7% above its year-end 2025 level. The company is stocking parts and finished machines ahead of shipping roughly 48 Atera systems in the fourth quarter, tying up working capital before those deliveries turn into sales.
The share count grew 4.2% from a year ago because the group pays employees heavily in stock and does not buy back shares. Stock-based compensation was $23.1 million, or 15.3% of revenue, down from 17.0% of revenue a year earlier on smaller research staff grants.
🔮 Guidance
Raised. The middle of the full-year outlook moved up $10 million to $630 million, which is 4% to 6% growth over 2025 excluding one-time patent settlement payments. By our math, that leaves $177.5 million for the fourth quarter at the middle of the range, up 6.9% from a year ago and up 17.8% from the third quarter. It is the second raise this year (+$7.5 million in Q2, +$10 million in Q3).
Raised. The genetic-analysis firm increased its first-year delivery plan by 10 machines, or 25%, after factory production ramped smoothly. Because only a couple of units shipped in late September, by our math the plan requires delivering roughly 48 machines in the fourth quarter.
New. Taich forecast that gross margin will drop by more than 10 percentage points from the third quarter's 75.0%. The step-down happens because hardware carries a lower profit margin than chemical kits, and fourth-quarter sales will include nearly 50 Atera instruments.
❓ Key Questions
How many top drugmakers bought Atera versus using the service lab?
Nearly all top 20 pharmaceutical firms used Atera or booked Catalyst lab projects, but Saxonov declined to split the two. Buying a machine commits a customer to years of chemical kit purchases, while a service project can be a one-off test.
What is the unit backlog for Atera heading into 2027?
Saxonov projected shipping about 50 machines a quarter next year and said production is the only bottleneck. Without a disclosed backlog number or rising customer deposits on the balance sheet, investors cannot verify how many quarters of orders sit in hand.
When will single-cell chemical revenue grow in line with test volumes?
Single-cell test volumes grew by double digits while revenue rose 0.7% because customers switched to lower-priced Flex Apex kits. Management has not said which quarter in 2027 the price drag will finish lapping.
What is the risk from the patent lawsuit against Xenium?
Legal expenses rose in the third quarter, and a lawsuit filed in August seeks to block sales of Xenium, the product driving 16% spatial kit growth. Management gave no update on the case's timeline or financial exposure.